Lytix Biopharma AS (STU:6BG) OCF Margin %: 0.00% (As of Mar. 2026)


STU:6BG Lytix Biopharma AS STU:6BG
30 GF Score
Price €0.80
GF Value €0.01
! 2 Warning Signs
View Full Analysis

What is Lytix Biopharma AS OCF Margin %?

Lytix Biopharma AS STU:6BG -3.37% 30 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates STU:6BG with a GF Score™ of 30/100 and a GF Value™ of €0.01. The stock has 2 warning signs investors should review. Among 948 Biotechnology companies, Lytix Biopharma AS ranks worse than 105485.13% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Lytix Biopharma AS's Cash Flow from Operations for the three months ended in Mar. 2026 was €-2.58 Mil. Lytix Biopharma AS's Revenue for the three months ended in Mar. 2026 was €0.00 Mil. Therefore, Lytix Biopharma AS's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Lytix Biopharma AS's current OCF Yield % is -10.37%.

The historical rank and industry rank for Lytix Biopharma AS's OCF Margin % or its related term are showing as below:


During the past 8 years, the highest OCF Margin % of Lytix Biopharma AS was -231.04%. The lowest was -811566.67%. And the median was -2404.64%.

STU:6BG's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -64.565
* Ranked among companies with meaningful OCF Margin % only.

Lytix Biopharma AS OCF Margin % Related Terms

Lytix Biopharma AS OCF Margin % Historical Data

* Premium members only.

The historical data trend for Lytix Biopharma AS's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lytix Biopharma AS OCF Margin % Chart

Lytix Biopharma AS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial -231.00 -477.04 -2,404.03 -631.86 0.00

Lytix Biopharma AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:6BG
30GF Score
Lytix Biopharma AS STU:6BG
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lytix Biopharma AS OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Lytix Biopharma AS's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-5.057/0
= %

Lytix Biopharma AS's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-2.576/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Lytix Biopharma AS (STU:6BG) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Lytix Biopharma AS and its competitors. According to the industry distribution chart, Lytix Biopharma AS ranks #999999 out of 948 companies in the Biotechnology industry.
Is Lytix Biopharma AS's OCF Margin % too high?
Lytix Biopharma AS's current OCF Margin % is 0.00%. Based on the distribution chart, Lytix Biopharma AS ranks #999999 out of 948 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lytix Biopharma AS has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Lytix Biopharma AS's OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lytix Biopharma AS ranks #999999 out of 948 companies for OCF Margin %. This places Lytix Biopharma AS in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Lytix Biopharma AS and its competitors. Lytix Biopharma AS's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lytix Biopharma AS stock overvalued right now?
Lytix Biopharma AS (STU:6BG) has a current OCF Margin % of 0.00%. The stock's GF Value™ is €0.01, compared to a current price of €0.80 — trading 7940% above its estimated fair value. The current OCF Margin % is 0.00%. Lytix Biopharma AS's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Lytix Biopharma AS (STU:6BG), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lytix Biopharma AS (STU:6BG) Overvalued in 2026?

Based on GuruFocus' analysis, Lytix Biopharma AS stock appears to be overvalued. The current stock price of €0.80 is trading 7940% above its estimated GF Value™ of €0.01.

Key valuation signals for STU:6BG:

  • OCF Margin %: 0.00%
  • GF Value™: €0.01 vs. price of €0.80 (7940% above fair value)
  • GF Score™: 30/100 with 2 warning signs

No single metric tells the full story. See the STU:6BG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lytix Biopharma AS Business Description

Other Exchanges LYTIX:Norway
Address Sandakerveien 138, Oslo, NOR, 0484
Lytix Biopharma AS is a clinical-stage biotech company engaged in developing cancer immunotherapies aimed at activating the patient's immune system to fight cancer. The company's technology platform is designed to convert immunologically "cold" tumors into "hot" tumors by releasing tumor antigens and activating tumor-specific immune responses. The product pipeline of the company includes LTX-401 and LTX-315. The company operates in Norway and the USA, majority of revenue is from the USA.
30GF Score

Get the complete analysis for STU:6BG

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.80
Price
€0.01
GF Value